On Tuesday, Recursion Pharmaceuticals (RXRX) stock reached a key performance benchmark, with its Relative Strength (RS) Rating rising into the 90-plus percentile with an improvement to 92, a rise from 64 the day before. This unique rating identifies technical performance by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks…
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.